AAAmanda I. Adler

Amanda I. Adler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amanda I. Adler has a total of 388 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-world evidence for decisions in diabetes

    by Shivani Misra, Monika Cigler, Omaima El-Hakouni, Martina Vettoretti, Enrico Longato, Jonah Thomas, Christian Torp-Pederson, Jonathan Valabhji, Amanda Adler, Bastiaan de Galan, et al.

  • Long-term Glycemia and Risk of Death in Cystic Fibrosis–Related Diabetes: A UK Cystic Fibrosis Registry Study

    by Amanda I. Adler, Brian Shine, Joanna Snowball, Charles Haworth

    OBJECTIVE: Mortality risk is increased in cystic fibrosis (CF)–related diabetes, but its relationship with long-term glycemia is unclear. RESEARCH DESIGN AND METHODS: Using UK Cystic Fibrosis Registry data, we estimated the association between updated interval mean hemoglobin A1c (HbA1c) and mortality using Poisson regression to estimate mortality rates adjusted for age and sex and rate ratios adjusted for age, calendar year, sex, BMI, pulmonary function, and use of CF transmembrane conductance regulator modulators. RESULTS: Of 4,477 individuals contributing 31,311 person-years of follow-up, 758 died. Mortality rates increased progressively with higher updated interval mean HbA1c values. Compared with HbA1c ≤42 mmol/mol, adjusted mortality rate ratios were 1.41 (95% CI 1.15–1.73) for HbA1c >42–53 mmol/mol, 1.66 (95% CI 1.33–2.07) for HbA1c >53–69 mmol/mol, and 1.93 (95% CI 1.53–2.43) for HbA1c >69 mmol/mol. CONCLUSIONS: Higher HbA1c was associated with a clinically and statistically significant increase in mortality among individuals with CF-related diabetes.

  • Open Access

    SGLT2 Inhibitor Use in Type 2 Diabetes in England: A Population‐Based Cross‐Sectional Study of Uptake of NICE Guidance

    by Patrick Muller, Jonathan Wray, Muksitur Rahman, James Hawkins, Chirag Bakhai, Daniel J. Cuthbertson, Robert Willans, Eleanor Yelland, Shaun Rowark, Magdalena Watras, et al.

    Aims: An update to the NICE Type 2 diabetes (T2DM) guideline in February 2022 recommended an SGLT2 inhibitor be offered to people with cardiovascular disease (CVD) or heart failure (HF) as comorbidities and considered for people at high CVD risk. We report uptake of this guideline in England 18 months after its publication. Materials and Methods: Observational cohort study using Clinical Practise Research Data Link records linked to hospital admissions. Presence of a current prescription for an SGLT2 inhibitor was evaluated in people with T2DM on 1 September 2023, stratified by CVD category (CVD only; HF only; both; high CVD risk; low CVD risk) and chronic kidney disease status, and by age, gender, ethnicity, deprivation and T2DM duration. Adjusted associations between patient characteristics and uptake were evaluated using logistic regression. Results: In the cohort of 587 826 people with T2DM, the percentage with a current prescription was 19.5% for people with CVD, 29.4% for people with HF, 30.5% for people with both CVD and HF, and 19.9% and 20.2% respectively for people at high and low CVD risk. In age‐stratified analyses, uptake was higher in people with more comorbidities. In adjusted models, uptake was lower in people aged > 60, women, Black people and people living in areas of higher deprivation. Conclusions: Whilst prescribing of SGLT2 inhibitors continues to rise in England, recent trends indicate an opportunity remains to increase uptake. Action is necessary to address inequalities by ethnicity and deprivation, and lower uptake for people with T2DM and CVD without HF.

  • Open Access

    Participants’ experiences of living with cystic fibrosis related diabetes and using a hybrid closed-loop system to support self-management: qualitative study

    by Julia Lawton, Amanda I. Adler, Amanda Brennan, Richard I. G. Holt, Roman Hovorka, Nithya Kadiyala, Dawn Lau, Marian Peacock, Charlotte K. Boughton, David Rankin

    Background: Cystic fibrosis-related diabetes (CFrD) is a common complication of cystic fibrosis (CF). Many people with CFrD struggle to keep glucose within target range leading to poorer clinical outcomes and reduced life expectancy. Hybrid closed-loop (HCL) systems are an exciting innovation which may help people with CFrD improve their glucose management and experience a better quality-of-life. We explored the experiences of adults with CFrD who used the CamAPS FX HCL to: understand the benefits and challenges to using HCL in people with CFrD; and, help inform decision-making about HCL use in CFrD populations in routine clinical care. Methods: We interviewed 19 individuals who used the CamAPS FX HCL for ≥ 3 months during the CL4P-CF clinical trial. Data were analysed thematically. Results: Participants reported multiple clinical and quality-of-life benefits to using HCL. Many described treatment burnout before using the system and, hence, benefitting from automated glucose regulation and an increased capacity to take on new activities. Participants also shared historical difficulties gaining/maintaining weight as a result of their CF and described how using the system helped them achieve weight/muscle gain, improved their bodily confidence and enabled to them to enjoy a greater diversity of foods. Participants also observed CF-related benefits, including a (perceived) reduced susceptibility to infections, improved mood/energy to take on CF management-tasks, and increased confidence and ability to undertake physical activity due to a reduced risk of hypoglycaemia. In addition, participants reported medical trauma arising from hospital admissions in childhood and exposure to medically-invasive procedures for their CF, and highlighted benefits to using a system which mitigated the need to use injections. Due to their earlier traumatic experiences, some expressed a preference for using tubeless pumps and cannulas that require less frequent replacement. Conclusions: Participants reported improved glucose management, CF-related benefits and wide-ranging quality-of-life gains resulting from HCL use. Given their earlier experiences of treatment burnout and medically-related trauma, and taking account of the distinctive challenges involved in managing CFrD, our findings suggest that people with CFrD are a uniquely deserving group for access to HCL technology if shown to be clinically and cost effective in this population. Trial registration: ClinicalTrials.gov: NCT05562492, registration date 28th September 2022.

  • Open Access

    Optimal Clinical Trials Platform for Progressive Multiple Sclerosis (OCTOPUS): protocol for an international, multi-arm, multi-stage, platform, randomized controlled, double-blind, phase 3 clinical trial

    by Sean Apap Mangion, Charles Wade, Cheryl Pugh, Matthew Burnell, Rachel Burton, Mary Rauchenberger, Hannah Sweeney, Aoife Nolan, Monica Lewis, Elizabeth Brodnicki, et al.

    Introduction: Current treatments for multiple sclerosis (MS) do not address the pathological processes of neurodegeneration and chronic demyelination. This, coupled with the significant challenges of translating promising phase 2 results to phase 3 trial success, highlights the need for more efficient trial designs, such as platform multi-arm multi-stage (MAMS) trial approaches. MAMS trials have demonstrated success in areas such as oncology and infectious diseases. They are typified by a statistically robust core trial design that allows the addition of further treatment arms and utilisation of interim outcome analyses at pre-defined timepoints, to determine whether to terminate a treatment arm early or proceed to the final outcome analysis. To address the challenges in progressive multiple sclerosis (PMS) treatment discovery, the Optimal Clinical Trials Platform for PMS (OCTOPUS) trial was developed. It currently utilises MRI whole-brain atrophy as its interim outcome measure and the clinically relevant composite Expanded Disability Status Scale Plus (EDSS-Plus) as its final outcome measure. A rigorous and systematic drug selection process that assessed preclinical in vitro and animal model evidence, along with additional human data, led to the prioritisation of R/S-alpha lipoic acid (R/S-ALA) and metformin for testing against placebo, targeting pathobiological mechanisms relevant to PMS. All participants will be eligible to receive the current standard of care, including disease-modifying treatments (DMTs). Method and analysis: OCTOPUS will be a multi-centre, randomised, placebo-controlled, double-blind, phase 3, MAMS trial of participants aged 25 to 70 years (inclusive) with PMS and an EDSS score of 4.0 to 8.0 (inclusive). Steady progression must be the major cause of increasing disability rather than relapse in the preceding 2 years. In the trial’s first candidate drug cycle, participants will be allocated to R/S-ALA, metformin, or placebo in a 1:1:1 ratio. Cycle 1 active treatments will start as R/S-ALA 600 mg once daily, increased after 4 weeks to 600 mg twice daily, or metformin 1 g once daily, increased after 4 weeks to 1 g twice daily. The trial will be multinational, with participation from 28 hospitals across the UK and 10 hospitals in Australia. Clinician-reported measures will include: the EDSS-Plus and the individual components: EDSS, Timed 25 Foot Walk (T25FW); 9 Hole Peg Test (9HPT); Symbol Digit Modalities Test (SDMT); Sloan Low Contrast Visual Acuity (SLCVA); and Relapse assessment. Patient-reported outcomes include MS specific walking, fatigue, pain, and impact scales. We will include a health economic analysis. Analysis stage 1 will require randomisation of 125 participants per arm and utilise MRI percentage brain volume change (PBVC) with the Structural Image Evaluation using Normalisation of Atrophy (SIENA) technique from baseline to 78 weeks. A positive outcome in analysis stage 1 will detect a 0.15% per year whole brain atrophy difference with a one-sided alpha of 0.35 and power of 95%, ensuring a low probability of erroneously rejecting a treatment arm at this stage. Any arms that show a positive effect will proceed to final analysis stage 2. Analysis stage 2 will require 600 participants per arm. Participants included in stage 1 will also be included in the stage 2. Analysis stage 2 will evaluate time to 6-month confirmed disability progression in the EDSS-Plus, in order to detect a 25% hazard ratio reduction with 90% power and an alpha of 0.05. Assuming one treatment arm proceeds to analysis stage 2, the trial will recruit approximately 1,200 participants and last about 6 years. This is approximately two-thirds the size and half the duration of separately conducted two-arm phase 2 and 3 trials. Ethics and dissemination: The protocol was approved by the London Hampstead REC (22/LO/0622). This manuscript is based on protocol version 8.0 , 28 th August 2025. The findings of this trial will be disseminated through peer-reviewed publications and conference presentations. There will be a close communication strategy developed with the UK MS Society (MSS) and full patient and public involvement and engagement (PPIE). Trial registration: ISRCTN: 14048364 EudraCT number: 2021-003034-37 CTA 20363/0445 IRAS number: 1003943 Secondary identifying numbers: ND001, CPMS 54274 Strengths and limitations: The OCTOPUS trial will be the first platform multi-arm multi-stage phase 3 trial in PMS, offering the potential to significantly expedite clinical trial processes with advantages in cost- and time-efficiency, focusing specifically on the poorly treated pathobiological processes of chronic neurodegeneration and demyelination It will begin by assessing two promising drug candidates, immediate-release metformin and R/S-ALA, and will expand over the duration of the trial to include more drug arms under the same trial master protocol The flexible and statistically robust trial design means that several components of the design (such as the early analysis stage 1 interim outcome) can be updated in line with evolving scientific knowledge It will ultimately be the largest ever investigator-initiated phase 3 trial in PMS It will include a range of national and international trial sites, including neuroscience centres and district general hospitals It will have a high inclusion limit for age (up to 70 years) and disability (up to EDSS 8.0) Several components (the telephone EDSS and virtual patient-reported outcome measures) will be amenable to remote collection increasing inclusivity and thus addressing public and participant suggestions, while minimising the risk of missing data The main challenges in this trial design are the statistical and methodological complexity involved in design and implementation, and interpretation of interim trial results. Conclusion: The trial launched cycle 1 in January 2023. Analysis stage 1 recruitment of 375 participants was achieved in November 2024, enabling planned interim analysis stage 1 to be conducted by late 2026 ( Figure 1 ). On the 1 st of June 2026, in the UK, 24 sites are active with a further 4 in set-up as part of stage 2, and in the Australian extension, Platform Adaptive Trial for Remyelination and Neuroprotection in Multiple Sclerosis (PLATYPUS), 1 site is active, with 9 additional sites in set-up.


  • Open Access

    PERsonalised Medicine for Intensification of Treatment (PERMIT) in type 2 diabetes mellitus: a target trial emulation from routine data

    by David G Lugo-Palacios, Patrick Bidulka, Paul Charlton, Bill Huston, Anna Carnegie, Orlagh Carroll, Stephen O’NEill, Amanda I Adler, Anirban Basu, Richard J Silverwood, et al.

    Background: Evidence is required on the relative effectiveness of sulphonylureas, dipeptidyl peptidase-4 inhibitors or sodium–glucose cotransporter 2 inhibitors added to metformin for people with type 2 diabetes mellitus. Objectives: To assess disparities in the initiation of second-line antidiabetic treatments prescribed among people with type 2 diabetes mellitus in England according to ethnicity and social deprivation. To compare the effectiveness of sulphonylureas, dipeptidyl peptidase-4 inhibitors and sodium–glucose cotransporter 2 inhibitors added to metformin for people with type 2 diabetes mellitus who require second-line treatment in routine clinical practice. To examine heterogeneity in the comparative short-term (12 months) effectiveness of sulphonylureas versus dipeptidyl peptidase-4 inhibitors combined with metformin on levels of glycated haemoglobin across the entire target population and subpopulations of decision-making relevance. To assess the comparative effectiveness of sulphonylureas, dipeptidyl peptidase-4 inhibitors or sodium–glucose cotransporter 2 inhibitors added to metformin according to individual risk-factor profiles of multiple long-term conditions. To calibrate the RAPIDS microsimulation model to UK data and then use the resultant RAPIDS-UK model to predict probabilities of long-term complications for people with type 2 diabetes mellitus in England after second-line treatment with sulphonylureas, dipeptidyl peptidase-4 inhibitors or sodium–glucose cotransporter 2 inhibitors added to metformin. Methods: We included adults with type 2 diabetes mellitus who initiated second-line antidiabetic treatment with sulphonylureas, dipeptidyl peptidase-4 inhibitors or sodium–glucose cotransporter 2 inhibitors added to metformin monotherapy. We used data from the Clinical Practice Research Datalink linked to Hospital Episode Statistics and the Office of National Statistics. We applied target trial emulation and instrumental variable analyses to reduce the risks of biases, including confounding. The primary outcome was change in mean glycated haemoglobin (mmol/mol) at 1-year follow-up. Secondary outcomes: change in mean body mass index, systolic blood pressure, estimated glomerular filtration rate and time to major adverse kidney event, major adverse cardiovascular event, heart failure hospitalisation, eye disease, amputation and all-cause mortality. We assessed treatment effect heterogeneity according to multiple long-term conditions. We used a microsimulation model to report the impact on long-term complications. Results: After the instrumental variable analysis, the mean 95% confidence interval differences in glycated haemoglobin change between baseline and 1 year were: −2.5 mmol/mol (−3.7 to −1.3) for sodium–glucose cotransporter 2 inhibitors versus sulphonylureas, and −3.2 mmol/mol (−4.6 to −1.8) for sodium–glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. Sodium–glucose cotransporter 2 inhibitors were more effective in reducing body mass index and systolic blood pressure compared to either sulphonylureas or dipeptidyl peptidase-4 inhibitors. Sodium–glucose cotransporter 2 inhibitors were also more effective at reducing mean glycated haemoglobin at 2-year follow-up, at reducing body mass index and systolic blood pressure at 1- and 2-year follow-ups and at reducing the hazards of heart failure hospitalisation (vs. dipeptidyl peptidase-4 inhibitors) and ≥ 40% decline in estimated glomerular filtration rate (vs. sulphonylureas). We did not find evidence of treatment effect heterogeneity by baseline cardiovascular disease status or multiple long-term condition profiles. The microsimulation model found that sodium–glucose cotransporter 2 inhibitors led to lower predicted incidence of end-stage kidney disease, heart failure and eye disease. Public and patient involvement translation workshop participants provided valuable insights on how best to share our findings. Limitations: We could only partially evaluate the main instrumental variable assumptions. Conclusions: We found that sodium–glucose cotransporter 2 inhibitors were better than dipeptidyl peptidase-4 inhibitors and sulphonylureas at improving important risk factors and at reducing the risk of complications among a general population of people with type 2 diabetes mellitus. Future work: Newer antidiabetic treatments should be evaluated. Funding: This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number NIHR128490.

  • Open Access

    Partial restoration of counterregulatory circulating glucagon by dapagliflozin and low-dose glibenclamide in men with type 1 diabetes: in vitro studies and randomised clinical crossover trial

    by Rui Gao, Ioannis Spiliotis, Haiqiang Dou, Thomas G. Hill, Lakshmi Kothegala, Caroline Miranda, Nkemjika Abiakam, Ruth L. Coleman, Sarah White, Amanda Adler, et al.


  • Open Access

    SGLT2 inhibitor use in type 2 diabetes in England: a population-based cross-sectional study of uptake of NICE guidance

    by Patrick Muller, Jonathan Wray, Muksitur Rahman, James Hawkins, Chirag Bakhai, Daniel J Cuthbertson, Robert Willans, Eleanor Yelland, Shaun Rowark, Magdalena Watras, et al.

    Aims: An update to the NICE Type 2 diabetes (T2DM) guideline in February 2022 recommended an SGLT2 inhibitor be offered to people with cardiovascular disease (CVD) or heart failure (HF) as comorbidities and considered for people at high CVD risk. We report uptake of this guideline in England 18 months after its publication. Materials and Methods: Observational cohort study using Clinical Practice Research Data Link records linked to hospital admissions. Presence of a current prescription for an SGLT2 inhibitor was evaluated in people with T2DM on 1 st September 2023, stratified by CVD category (CVD only; HF only; both; high CVD risk; low CVD risk) and chronic kidney disease status, and by age, gender, ethnicity, deprivation, and T2DM duration. Adjusted associations between patient characteristics and uptake were evaluated using logistic regression. Results: In the cohort of 587,826 people with T2DM, the percentage with a current prescription was 19.5% for people with CVD, 29.4% for people with HF, 30.5% for people with both CVD and HF, and 19.9% and 20.2% respectively for people at high and low CVD risk. In age-stratified analyses uptake was higher in people with more comorbidities. In adjusted models, uptake was lower in people aged >60, women, Black people, and people living in areas of higher deprivation. Conclusions: Whilst prescribing of SGLT2 inhibitors continues to rise in England, recent trends indicate an opportunity remains to increase uptake. Action is necessary to address inequalities by ethnicity and deprivation, and lower uptake for people with T2DM and CVD without HF.


  • Open Access

    Missing Pieces of the Puzzle to Address Market Failures for Antibiotics: Delinked Payment Systems and Insurance Value

    by Neil Hawkins, Adrian Towse, Amanda Adler

    Too few companies develop new antibiotics because of the threat of market failure. To address this, a ‘delinked’ payment, distinct from the usual payment model for drugs, makes payments to manufacturers that do not depend on the volume of antibiotic prescribed. A delinked system removes incentives to overpromote antibiotic use. If total payments are high enough, this system should provide incentives for manufacturers to develop new antibiotics. This assumes that using antibiotics remains consistent with antimicrobial stewardship, a coordinated approach to prescribing antimicrobials responsibly. A delinked system can address market failure that occurs when a disproportionate degree of clinical benefit from a new antibiotic occurs after patent protection ends, reducing the ‘reward’ to the innovator. Determining value in a delinked payment system requires that the health service estimates the lifetime value of an antimicrobial product, and then decides what proportion of that value to include. These values depend in part on ‘STEDI’ values including the ‘insurance’ value new antibiotics would offer in reducing society’s risk of major health loss from possible future major episodes of antibiotic resistance. Estimating insurance value requires estimating the health consequences of catastrophic outcomes. Payments in a delinked system can incorporate an ‘insurance premium’. We use the example of the UK’s delinked payment scheme to illustrate issues and solutions.